Clinical Trials
393 trialsTRIFOUR
Cantargia AB
A Phase Ib/II Clinical Study Evaluating HMPL-453 Tartrate as Monotherapy and in Combination With Chemotherapy or Toripalimab in Advanced Solid Tumors
Hutchmed
Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients
Trishula Therapeutics, Inc.
EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma
NovoCure Ltd.
INFINITE
Ferring Ventures Limited
NAPOLI 3
Ipsen
KEYNOTE-966
Merck Sharp & Dohme LLC
HCW9218 for Advanced Pancreatic Cancer
ImmunityBio, Inc.
TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Lumos Pharma
A Study of Azenosertib (ZN-c3) in Combination With Gemcitabine in Subjects With Osteosarcoma
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors
Nanjing Leads Biolabs Co.,Ltd
A Study to Assess an ATX Inhibitor (IOA-289) in Patients With Metastatic Pancreatic Cancer
iOnctura
KEYNOTE-966
Merck Sharp & Dohme LLC
KEYLYNK-009
Merck Sharp & Dohme LLC
LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer
Lokon Pharma AB
A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
Janssen Research & Development, LLC
innovaTV 301
Seagen Inc.
Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)
Regeneron Pharmaceuticals
KEYNOTE-B15
Merck Sharp & Dohme LLC
A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)
Hoffmann-La Roche
Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)
Hoffmann-La Roche
Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)
NovoCure Ltd.
MK-4280A-008
Merck Sharp & Dohme LLC
A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)
UroGen Pharma Ltd.
A Study Describing Real-World Effectiveness of Nivolumab + Chemotherapy in Neoadjuvant NSCLC
Bristol-Myers Squibb
CheckMate 816
Bristol-Myers Squibb
POLARGO
Hoffmann-La Roche
A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
Hoffmann-La Roche
CUPISCO
Hoffmann-La Roche
IMpassion132
Hoffmann-La Roche
CheckMate 227
Bristol-Myers Squibb
TRESR
Repare Therapeutics
A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Jazz Pharmaceuticals
KEYVIBE-005
Merck Sharp & Dohme LLC
A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors
Incyte Corporation
A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer
Jiangsu HengRui Medicine Co., Ltd.
Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder
Leap Therapeutics, Inc.
Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab
Leap Therapeutics, Inc.
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
Trishula Therapeutics, Inc.
TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers
Trishula Therapeutics, Inc.
MK-0482-001
Merck Sharp & Dohme LLC
SQUIRE
Eli Lilly and Company
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
NGM Biopharmaceuticals, Inc
MAESTRO
ImmunoGenesis
VIRAGE
Theriva Biologics SL
BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients
BPGbio
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
EpicentRx, Inc.
A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal Carcinoma
Akeso